178 related articles for article (PubMed ID: 37962334)
21. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis.
Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP
Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405
[TBL] [Abstract][Full Text] [Related]
22. Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation.
Castagnola E; Mesini A; Saffioti C; Barco S; Bandettini R; Dallorso S; Carrega G; Miano M; Palmisani E; Dufour C
J Chemother; 2020 Jul; 32(4):217-218. PubMed ID: 32364049
[TBL] [Abstract][Full Text] [Related]
23. New pharmacological opportunities for the treatment of invasive mould diseases.
Ledoux MP; Toussaint E; Denis J; Herbrecht R
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i48-i58. PubMed ID: 28355467
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
25. Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?
Fung M; Schwartz BS; Doernberg SB; Langelier C; Lo M; Graff L; Tan M; Logan AC; Chin-Hong P; Babik JM
Clin Infect Dis; 2018 Sep; 67(7):1142-1143. PubMed ID: 29617983
[No Abstract] [Full Text] [Related]
26. The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation.
Winiszewski H; Rougny AC; Lagoutte-Renosi J; Millon L; Capellier G; Navellou JC; Piton G; Clairet AL
Crit Care; 2018 Dec; 22(1):355. PubMed ID: 30577863
[No Abstract] [Full Text] [Related]
27. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
28. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
29. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
30. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
[TBL] [Abstract][Full Text] [Related]
31. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
Monzó-Gallo P; Lopera C; Badía-Tejero AM; Machado M; García-Rodríguez J; Vidal-Cortés P; Merino E; Calderón J; Fortún J; Palacios-Baena ZR; Pemán J; Sanchis JR; Aguilar-Guisado M; Gudiol C; Ramos JC; Sánchez-Romero I; Martin-Davila P; López-Cortés LE; Salavert M; Ruiz-Camps I; Chumbita M; Aiello TF; Peyrony O; Puerta-Alcalde P; Soriano A; Marco F; Garcia-Vidal C
Int J Infect Dis; 2024 Jul; 144():107070. PubMed ID: 38663477
[TBL] [Abstract][Full Text] [Related]
32. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
33. Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.
Cummins KC; Cheng MP; Kubiak DW; Davids MS; Marty FM; Issa NC
Leuk Lymphoma; 2019 Feb; 60(2):527-530. PubMed ID: 30037292
[No Abstract] [Full Text] [Related]
34. Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
Hsu AJ; Tamma PD; Fisher BT
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0215621. PubMed ID: 35766509
[TBL] [Abstract][Full Text] [Related]
35. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.
Rausch CR; DiPippo AJ; Bose P; Kontoyiannis DP
Clin Infect Dis; 2018 Oct; 67(10):1610-1613. PubMed ID: 29771293
[TBL] [Abstract][Full Text] [Related]
36. Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.
Jeck J; Wingen-Heimann SM; Jakobs F; Kron A; Franz J; Cornely OA; Kron F
Mycoses; 2023 May; 66(5):405-411. PubMed ID: 36670539
[TBL] [Abstract][Full Text] [Related]
37. Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies.
Gatti M; Campoli C; Belotti T; Cojutti PG; Masetti R; Pession A; Viale P; Pea F
Ther Drug Monit; 2022 Oct; 44(5):641-650. PubMed ID: 35344524
[TBL] [Abstract][Full Text] [Related]
38. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
[TBL] [Abstract][Full Text] [Related]
39. Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study.
Thompson GR; Garcia-Diaz J; Miceli MH; Nguyen MH; Ostrosky-Zeichner L; Young JH; Fisher CE; Clark NM; Greenberg RN; Spec A; Kovanda L; Croos-Dabrera R; Kontoyiannis DP
Mycoses; 2022 Feb; 65(2):186-198. PubMed ID: 34888961
[TBL] [Abstract][Full Text] [Related]
40. Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease.
Zhang J; Zhang Y; Wu D; Cao G; Hamed K; Desai A; Aram JA; Guo X; Fayyad R; Cornely OA
Future Microbiol; 2022 Oct; 17():1203-1206. PubMed ID: 35916057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
